WO2007047838A3 - Process for preparing olmesartan medoxomil - Google Patents
Process for preparing olmesartan medoxomil Download PDFInfo
- Publication number
- WO2007047838A3 WO2007047838A3 PCT/US2006/040883 US2006040883W WO2007047838A3 WO 2007047838 A3 WO2007047838 A3 WO 2007047838A3 US 2006040883 W US2006040883 W US 2006040883W WO 2007047838 A3 WO2007047838 A3 WO 2007047838A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- olmesartan medoxomil
- methylethyl
- carboxylate
- propyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Olmesartan medoxomil, i.e. 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl] imidazole-5-carboxylate, cyclic 2,3-carbonate, is prepared. Precursors of Olmesartan medoxomil are prepared as well. In particular a process for the preparation of methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-2-(trityltetrazol-5-yl) phenyl} methyl imidazole-5-carboxylate and its use in the preparation of Olmesartan medoxomil is disclosed. Olmesartan medoxomil is a selective angiotensin Il receptor antagonist, pharmaceutically used as an antihypertensive.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1517/CHE/2005 | 2005-10-20 | ||
| IN1517CH2005 | 2005-10-20 | ||
| US74567006P | 2006-04-26 | 2006-04-26 | |
| US60/745,670 | 2006-04-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007047838A2 WO2007047838A2 (en) | 2007-04-26 |
| WO2007047838A3 true WO2007047838A3 (en) | 2007-12-06 |
Family
ID=37963278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2006/040883 Ceased WO2007047838A2 (en) | 2005-10-20 | 2006-10-18 | Process for preparing olmesartan medoxomil |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007047838A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0710905D0 (en) * | 2007-06-07 | 2007-07-18 | Generics Uk Ltd | Amorphous olmesartan medoxomil |
| KR101630885B1 (en) | 2008-06-09 | 2016-06-15 | 다이이찌 산쿄 가부시키가이샤 | Method for producing 1-biphenylmethylimidazole compound |
| WO2010026255A1 (en) * | 2008-09-05 | 2010-03-11 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for preparing olmesartan medoxomil intermediate |
| CA2760031C (en) * | 2009-04-28 | 2015-03-10 | Daiichi Sankyo Company, Limited | Acetone solvate crystals of trityl olmesartan medoxomil |
| ES2527686T3 (en) | 2009-04-28 | 2015-01-28 | Daiichi Sankyo Company, Limited | Olmesartan Medoxomil Production Procedure |
| WO2011007368A2 (en) | 2009-07-14 | 2011-01-20 | Cadila Healthcare Limited | An improved process for preparation of olmesartan |
| WO2011021224A2 (en) * | 2009-08-19 | 2011-02-24 | Msn Laboratories Limited | Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate |
| WO2011045760A2 (en) | 2009-10-13 | 2011-04-21 | Ranbaxy Laboratories Limited | Micronized olmesartan medoxomil compositions |
| AR083523A1 (en) | 2010-10-29 | 2013-03-06 | Interquim Sa | PROCEDURE FOR OBTAINING OLMESARTAN MEDOXOMILO |
| WO2014030082A1 (en) | 2012-08-22 | 2014-02-27 | Lupin Limited | Novel method to obtain olmesartan medoxomil with reduced particle size |
| JP6382660B2 (en) * | 2014-09-24 | 2018-08-29 | 株式会社トクヤマ | Method for producing olmesartan medoxomil |
| CN106749195A (en) * | 2016-12-30 | 2017-05-31 | 青岛黄海制药有限责任公司 | A kind of olmesartan medoxomil intermediate impurities synthesis, the method for identification |
| CN112337419B (en) * | 2020-10-27 | 2022-05-13 | 浙江花蝶染料化工有限公司 | Preparation method of 4- (1-hydroxy-1-methylethyl) -2-propylimidazole-5-carboxylic acid ethyl ester |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459148A (en) * | 1992-12-17 | 1995-10-17 | Sankyo Company, Limited | Biphenyl derivatives and their use for the treatment of hypertension and cardiac disease |
| US5646171A (en) * | 1991-02-21 | 1997-07-08 | Sankyo Company, Limited | Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use |
| US5674879A (en) * | 1993-09-24 | 1997-10-07 | G.D. Searle & Co. | Compositions including and methods of using conformationally restricted angiotensin II antagonist |
| US6878703B2 (en) * | 2000-11-21 | 2005-04-12 | Sankyo Company, Limited | Pharmaceutical composition |
-
2006
- 2006-10-18 WO PCT/US2006/040883 patent/WO2007047838A2/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646171A (en) * | 1991-02-21 | 1997-07-08 | Sankyo Company, Limited | Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use |
| US5459148A (en) * | 1992-12-17 | 1995-10-17 | Sankyo Company, Limited | Biphenyl derivatives and their use for the treatment of hypertension and cardiac disease |
| US5674879A (en) * | 1993-09-24 | 1997-10-07 | G.D. Searle & Co. | Compositions including and methods of using conformationally restricted angiotensin II antagonist |
| US6878703B2 (en) * | 2000-11-21 | 2005-04-12 | Sankyo Company, Limited | Pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007047838A2 (en) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007047838A3 (en) | Process for preparing olmesartan medoxomil | |
| WO2004096798A3 (en) | Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists | |
| WO2009013211A3 (en) | New pyrazol derivatives | |
| DE50309807D1 (en) | SELECTED CGRP ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DRUGS | |
| DE502005007786D1 (en) | SELECTED CGRP ANTAGONISTS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS DRUGS | |
| IL164584A (en) | 1-(4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists and pharmaceutical compositions comprising the same | |
| PL376373A1 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
| WO2009080721A3 (en) | 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists | |
| ZA200903578B (en) | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
| NZ552137A (en) | New 4-benzylidene-piperidin derivatives | |
| WO2011021224A3 (en) | Improved process for preparing (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-(tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate | |
| AU2003215549A1 (en) | Mercaptoimidazoles as ccr2 receptor antagonists | |
| WO2011007368A3 (en) | An improved process for preparation of olmesartan | |
| WO2008027523A3 (en) | Salts of benzimidazolyl pyridyl ethers and formulations thereof | |
| WO2005039639A3 (en) | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker | |
| WO2004075892A3 (en) | Combination therapy for hypertension using lercanidipine and an angiotensin ii receptor blocker | |
| SE0302571D0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| DE60116584D1 (en) | Metal-ceramic composite body as well as vacuum switch for its use | |
| IL183232A0 (en) | PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL AT pH HIGHER THAN 2.5 | |
| HK1052179A1 (en) | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists | |
| GB0004708D0 (en) | Restricting reinstatement of drug use | |
| HK1052181A1 (en) | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists | |
| EA201070361A1 (en) | (S) -2 - ((4-BENZOFURANILYL) CARBONYLAMINOMETHYL) -1 - ((4- (2-METHYL-5- (4-FLUOROPHENYL) | |
| HK1052180A1 (en) | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists | |
| WO2007039606A3 (en) | Insulin receptor antagonists and related compositions, uses and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1920/CHENP/2008 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06826274 Country of ref document: EP Kind code of ref document: A2 |